Background Tumor necrosis factor-a (TNF-a) has been reported to have an antiviral effect in vitro; however, its in vivo effect remains to be clarified.
Therapeutic Effect of Anti-Tumor Necrosis
Factor-a Antibody on the Murine Model of Viral Myocarditis Induced by Encephalomyocarditis Virus Takehiko Yamada, MD; Akira Matsumori, MD; Shigetake Sasayama, MD Background Tumor necrosis factor-a (TNF-a) has been reported to have an antiviral effect in vitro; however, its in vivo effect remains to be clarified.
Methods and Results To investigate the role of TNF-a in viral myocarditis using a murine model induced by encephalomyocarditis virus (EMCV), we evaluated (1) plasma TNF-a levels by enzyme-linked immunosorbent assay (ELISA), (2) the effect of recombinant human TNF-a for its possible antiviral effect in vivo, and (3) the effect of anti-murine TNF-a monoclonal antibody (mAb) in vivo. Four-week-old DBA/2 mice were inoculated intraperitoneally with EMCV (day 0). Mice were injected intravenously daily with 1 ,ug of TNF-a or 2x 103 units of anti-TNF-a mAb starting on day -1, day 0, or day 1 until day 2 (TNF-a study) or day 4 (anti-TNF-a mAb study). A portion of the mice were killed on day 5 (protocol 1); their hearts were removed, and plaque assays were performed to demonstrate the myocardial virus content. The remaining mice were killed on day 14 (protocol 2); myocardial lesions T umor necrosis factor-a (TNF-a), a cytokine mainly released by activated macrophages, was initially reported as an antitumor agent.1 Since that time, knowledge about the biological effects of TNF-a has significantly increased.2 Many of the activities attributed to TNF-a overlap with other cytokines such as interleukin-1 (IL-1), interferons (IFNs), and interleukin-6 (IL-6).3 TNF-a has been recognized as a common mediator of the immune system. However, contrary to the data in vitro, little is known about the in vivo effects of TNF-a. Whether the effects of TNF-a are beneficial or deleterious to the host may depend on the circumstances involved, the amount of production, and whether it is endogenously produced or exogenously administered.4 In some instances, in vitro activity has been shown to contradict its activity in vivo. For instance, TNF-a inhibited endothelial cell growth in vitro but it was angiogenic in vivo.5 Recently, an in vitro antiviral effect of TNF-a has been reported in selected cell lines6-8; however, whether TNF-a is antiviral in vivo has not been established.9'10 Moreover, TNF-a is identical to cachectin,1" which causes shock and eventual death in mice.1213 Therefore, the doses, methods of were examined histopathologically in terms of severity, and their survival rates were determined. Plasma TNF-a concentration was elevated in the blood of infected mice compared with uninfected mice 3, 5, and 7 days after virus inoculation. The myocardial virus content was higher in the TNF-atreated group than in the control group. Histopathological analysis revealed that myocardial necrosis and cellular infiltration were more prominent in the TNF-a group than in the control group. The anti-TNF-a mAb improved survival and myocardial lesions when its treatment was started 1 day before virus inoculation. However, it showed no therapeutic effect when administered simultaneously with the inoculation or on day 1.
Conclusions TNF-a may play an important role in the very early stage of the immune response, and anti-TNF-a mAb may prevent the early pathway of acute viral myocarditis.
(Circulation. 1994;89:846-851.)
Key Words * myocarditis * viruses * antibodies administration, and protocols should be considered carefully in predicting its in vivo effect. In this study, we investigated a role of TNF-a in viral infection using an experimental model of murine viral myocarditis induced by encephalomyocarditis virus (EMCV), against which a novel antiviral effect of TNF-a was reported in vitro. 6 Massive inflammation occurs in the heart several days after viral infection, with severe myocardial necrosis and mononuclear cellular infiltration leading to congestive heart failure.'415 We first determined plasma TNF-a levels in EMCV-infected mice and then investigated the effects of a nonlethal dose of recombinant human TNF-a and anti-TNF-a monoclonal antibody (mAb) in this model of acute viral myocarditis.
Methods
Tumor Necrosis Factor-a Recombinant human TNF-a produced in Escherichia coli by recombinant DNA techniques and purified to homogeneity (.99% on the basis of SDS-PAGE analysis) as described previously16 was used (provided by Suntory Institute for Biochemical Research, Osaka, Japan). The specific activity of TNF-a was about 4.8x 10' units/mg of protein, based on its cytotoxic activity in L929 cells.
Mortality in Mice After Treatment With TNF-a
Because a high dose of TNF-a is lethal to mice, various doses were injected intravenously to normal DBA/2 mice to elucidate the acute toxic effect of TNF-a. The mice were observed for 48 hours after the treatment.
Virus and Cell
The M (myocardiotrophic) variant of EMCV was used. Virus stock was prepared as described previously14A5 and stored at -70°C until it was diluted for use. Mice were inoculated intraperitoneally with 0.1 mL of EMCV diluted in Eagle's minimum essential medium (MEM) to a concentration of 10 plaque forming units (pfu)/mL. Viral titers in the heart were determined by plaque formation on FL (human amnion) cells. Cells were suspended to a concentration of 2x 106/mL in Eagle's MEM with 10% fetal calf serum (FCS) plus 10 ,g/mL penicillin G and streptomycin in six-well plastic plates and were allowed to grow for 2 days at 37°C in 5% Co2.
Virus Inoculation and Treatment of Mice
A total of 270 4-week-old DBA/2 male mice were obtained from the Shizuoka Agricultural Cooperative Association (Shizuoka, Japan). The day of virus inoculation was defined as day 0 in the following studies. Mice were observed daily, and when found dead, necropsies were performed. Surviving mice were killed on day 5 (protocol 1) or on day 14 (protocol 2).
Plasma TNF-a Determination
Thirty mice were inoculated with 10 pfu/0.1 mL of EMCV on day 0. Mice were killed on days 1, 3, 5, and 7. Blood was obtained, and plasma TNF-a levels were determined using enzyme-linked immunosorbent assay (ELISA).
A solid-phase sandwich ELISA kit for murine TNF-a was used (Otsuka Pharmaceutical Co, Tokushima, Japan). Ninety-six-well microtest plates were coated with 100 ,L of anti-TNF-a monoclonal antibody per well. Between subsequent steps in the assay, the coated plates were washed three times in washing buffer. After 30 minutes of preincubation at 37°C in wash buffer, 100 ,uL of either standard TNF-a, control solution, or serum from the mice was added for 2 hours at 37°C. Goat polyclonal anti-murine TNF-a antibody then was added for 90 minutes followed by horseradish peroxidase-conjugated donkey anti-goat immunoglobulin antibody for 1-hour incubation at room temperature, whereby 100 ,uL of diluted o-phenyleneduamine was added. The enzyme reaction was stopped with 100 ,uL of 1 mol/L sulfuric acid, and the absorbance was measured at 492 nm using a microtest plate photometer.
TNF-cr Study
Each mouse in the TNF-a-treated groups was injected intravenously with 1 gg of TINF-a diluted in 0.1 mL of PBS. A total of 120 mice were inoculated. Mice were injected intravenously daily with 1 ,ug/0.1 mL of TNF-a started on day -1 (TNF -1D group: protocol 1, n= 10; protocol 2, n=20), simultaneous with virus infection (TNF ±OD group: protocol 1, n=10; protocol 2, n=20), and on day 1 (TNF +1D group: protocol 1, n=10; protocol 2, n=20) until day 2. Infected control mice were injected daily with 0.1 mL IV saline started on day -1 until day 2 (saline group: protocol 1, n= 10; protocol 2, n=20). The mice in protocol 1 were killed on day 5; their hearts were removed and weighed, and plaque assays for virus titers of the hearts were performed. The surviving mice in protocol 2 were killed on day 14 . Heart weight (HW) and body weight (BW) were measured, and HW to BW ratio (HW/BW) was calculated. Histopathological study was subsequently performed. Five mice were treated with TNF-a alone daily from day -1 until day 2 as an age-matched uninfected group (protocol 2, n=5).
Anti-TNF-a nmAb Study
One hundred fifteen mice were inoculated in the same way as in the TNF-a study. Mice were injected daily with 1 jig (2x 103 units) IV diluted in 0.1 mL PBS of anti-mouse TNF-a mAb (Genzyme) started on day -1 (AB-1D) group: protocol 1, n=10; protocol 2, n=18), and on day +1 (AB +1D group: protocol 1, n=10; protocol 2, n=16) until day 4. Infected control mice were injected daily with 0.1 mL IV saline started on day -1 until day 4 (saline group: protocol 1, n= 10; protocol 2, n= 18). Five mice were treated with anti-TNF-a mAb alone daily from day -1 until day 4 as an uninfected group (protocol 2, n=5). Mice were killed, and virus titers and histopathological lesions were defined in the same way as in the TNF-a study.
Virus Titers of Murine Hearts
For infectivity assay, hearts of infected mice were removed aseptically on day 5, and longitudinal halves were weighed and homogenized in 2 mL of Eagle's MEM. After centrifugation at 1500g for 15 minutes at 4°C, 0.1 mL of supernatant was inoculated into FL cell monolayers for 60 minutes at 37°C in 5% CO2. Cells then were overlaid with 3 mL of medium containing 4% FCS and 1% methylcellulose. After 2 days of incubation at 37°C in a humidified atmosphere containing 5% C02, cells were fixed with acetic acid and methanol (in a ratio of 1: 3) and stained with crystal violet (1%), and plaques were counted with an inverted microscope. The myocardial virus titer was expressed as logi0 pfu/mg. Histopathology
The other halves of the hearts on day 14 were fixed in 10% formalin and embedded in paraffin. Several sections were stained with hematoxylin and eosin and scored (0 to +4) by a blinded, skilled observer for myocardial necrosis and cellular infiltration. The mean value was cited. The scores were 0 (none), no myocardial lesion; 1+, lesions involving <25% of the myocardium; 2+, lesions involving 25% to 50% of the myocardium; 3+, lesions involving 50% to 75% of the myocardium; 4+, lesions involving >75% of the myocardium. Representative photomicrographs are shown in Fig 1. 
Statistical Analysis
Survival of mice was analyzed by the Kaplan-Meier method. Statistical comparisons of plasma TNF-a levels, BW, HW, BW/HW ratio, and histopathological scores were performed by one-way ANOVA. Differences were considered statistically significant at P<.05. Results are expressed as mean+SEM.
Results

Mortality After TNF-a Injection
Intravenous injection of 100 or 10 ,ug of TNF-a was lethal for normal DBA/2 mice 48 hours after treatment. Their mortality was 100% (10 of 10 mice) and 58% (11 of 19), respectively. However, 1 or 2 gg of TNF-a was not lethal for mice; mortality in each was 0% (0 of 10 each). Therefore, we chose the dose of 1 g.g to be injected per mouse in the TNF-a study. Plasma TNF-a Levels in Murine Viral Myocarditis
As shown in Fig 2, plasma TNF-a levels were elevated significantly (P<.05) in the blood of infected mice on day 3 (24.2±1.6 pg/mL), day 5 (37.8+2.1 pg/mL), and day 7 (25.7+1.0 pg/mL) in comparison with that of uninfected mice (20.7+1.3 pg/mL). Effect of TNF-a on Murine Viral Myocarditis
The survival rates of each infected group on day 14 were 47% in the saline group, 26% in the TNF -1D group, and 33% in the TNF +OD and TNF + 1D groups (Fig 3) . There were no significant differences in survival rates among the TNF-av-treated groups; however, a significant decrease was found when the survival rates 1, n = 10; protocol 2, n = 18), on day 0 (AB -+-OD group: protocol 
Effect of Anti-TNF-a mAb on Murine Viral Myocarditis
The survival rates on day 14 were 38% in the saline group, 67% in the AB -1D group, 38% in the AB ±OD group, and 20% in the AB + 1D group (Fig 4) . Significant increase of survival was found in the AB -1D group in comparison with that of the saline group (P<.05). Mean BW and mean HW decreased, and mean HW/BW ratio increased in the infected groups on day 14; they were significantly different from those in uninfected normal mice (Table 2 ). There was significant decrease of the HW/BW ratio in the AB -1D group in comparison with that of the saline group (P<.01). The histopathological scores of necrosis and cellular infiltration in the surviving mice on day 14 were significantly improved in the AB -1D group when they were compared with the saline group (P<.05). Discussion Elevated levels of plasma TNF-a have been reported in patients with infectious diseases17-20; however, the pathophysiological role is not well understood. In this study, plasma TNF-a concentration was elevated in the blood of EMCV-infected mice on days 3, 5, and 7 in comparison with that of uninfected mice. In this acute phase of viral myocarditis, viremia is predominant, and mice develop severe congestive heart failure.14"5 The cells that possibly produce TNF-a may be activated macrophages and lymphocytes infiltrating in the myocardium. In autopsy specimens of human myocarditis, mononuclear cells have been observed when stained with anti-TNF-a antibody. 2' Viruses are known to be one of the inducers of TNFa.22'23 The TNF-a production after injecting endotoxin (LPS) is reported to vary among strains of mice,24 suggesting that TNF-a production is genetically controlled by MHC. It is of interest that TNF-a genes are sited close to the MHC gene25 and TNF-a infusion increases HLA-DQ antigen expression.26 Virus susceptibility also is markedly different among strains of mice.27 B1O.A mice, resistant to coxsackievirus B3, developed autoimmune myocarditis with viral inoculation after pretreatment with LPS. 28 The high TNF-a production induced by LPS is considered to be related to virus susceptibility. Our results demonstrate that the myocardial virus content was higher in the TNFa-treated group than in the control group. Histopathological evaluation revealed that myocardial necrosis and cellular infiltration were more prominent in the TNF-a group. DBA/2 mice are highly susceptible to EMCV15 and also have high TNF-a-productive activity.24 Therefore, it may be possible that the injected TNF-a caused further susceptibility to EMCV leading to higher mortality and higher virus proliferation in this strain. On the other hand, the susceptibility to toxoplasmic encephalitis29 and radioresistence30 in mice has been also reported to be related to TNF-a gene induction. TNF-a infusion caused increased susceptibility in the former,29 and anti-TNF-a Ab aggravated mortality in the latter.30 These data suggest that TNF-a plays an important role in the primitive host defense or homeostasis against exogenous stress such as viruses, parasites, and radiation.
The antiviral effect of TNF-a in vitro was first reported against EMCV. The administration of anti-TNF-a (or anticachectin) Ab or passive immunization of TNF-a prevented septic shock caused by the intravenous infusion of LPS in mice.4546 The anti-TNF-a Ab showed a protective effect when it was given 2 hours before LPS administration, but it did not when it was given 1 hour before LPS.45 In our study, anti-TNF-a mAb improved survival and showed a protective effect when started 1 day (24 hours) before infection (AB -1D group). However, it did not alter their mortality or prevent myocardial lesions when anti-TNF-an mAb was given later. Anti-TNF-a mAb is reported to be effective in preventing acute cardiac rejection after heart transplantation in rats. 47 These data suggest that TNF-a plays a common and essential role in the very early stage of acute viral myocarditis. On the contrary, IFN-a showed an anti-EMCV effect in vivo in our murine model of viral myocarditis even when it was started simultaneously with virus infection but showed no effect when it was started 1 day after that.48 This suggests that IFN-a shows an antiviral effect even when virus replication in the heart has started. The anti-TNF-a Ab also suppresses cell-mediated immunity in vivo. It is of interest to note that anti-TNF-a Ab was effective during the afferent limb or priming limb of immunity, whereas it was ineffective during the efferent limb. 49 
Conclusions
Exogenously administered TNF-a aggravated EMCVinduced acute myocarditis in DBA/2 mice, although anti-TNF-a mAb improved the same model when its treatment was started 1 day before virus inoculation. Induced TNF-a level in the blood of infected mice 3, 5, and 7 days after the virus inoculation may not act as an antiviral agent similar to IFNs. However, TNF-a may play an important role in the very early stage of the immune system, and anti-TNF-a mAb may prevent the early pathway of acute viral myocarditis.
